Novartis' Pelacarsen Lowers Lp(a) but Misses Cardiovascular Endpoint in Phase 3 Lp(a)HORIZON
核心洞察
Novartis' pelacarsen significantly lowered lipoprotein(a) but failed to produce a statistically significant reduction in major cardiovascular events in the Phase 3 Lp(a)HORIZON trial.
The trial enrolled 8,323 patients with elevated Lp(a) (搜索) and established heart disease, testing whether biomarker lowering translates into fewer heart attacks and strokes.
Citi analysts expect the result to push CRISPR Therapeutics toward its more potent next-generation candidate CTX321 (搜索) over CTX320, which achieved up to 73% Lp(a) (搜索) reductions.
Novartis' pelacarsen significantly lowered lipoprotein(a) but did not produce a statistically significant reduction in major cardiovascular events in the Phase 3 Lp(a)HORIZON trial, the company has reported. The result leaves a central question in cardiovascular medicine unresolved: whether lowering Lp(a) (搜索) reduces residual cardiovascular risk beyond optimized, guideline-directed care.
The trial enrolled 8,323 patients who had elevated Lp(a) (搜索), a genetically inherited cholesterol-like particle, plus established heart disease. All participants were also on standard heart medications. Pelacarsen lowered Lp(a) (搜索) levels as intended, but fewer patients than hoped avoided the composite of cardiovascular death, heart attack, stroke or urgent artery procedures compared with placebo.
A Biomarker That Moved, an Outcome That Did Not
Pelacarsen is an antisense drug designed to inhibit the liver's production of apolipoprotein(a) (搜索), thereby reducing circulating Lp(a) (搜索). The large cardiovascular outcomes study was intended to determine whether that reduction translated into fewer cardiovascular events. It did not meet that endpoint.
"Lp(a)HORIZON was a pioneering cardiovascular outcomes trial designed to answer one of the most important unanswered questions in cardiovascular medicine by evaluating whether lowering Lp(a) (搜索) can reduce residual cardiovascular risk beyond optimized, guideline-directed care, when other major cardiovascular risk factors are already being managed," said Shreeram Aradhye, Novartis' President of Development and Chief Medical Officer.
Aradhye said that although lower Lp(a) (搜索) levels were observed with pelacarsen, the findings failed to demonstrate that this reduction translated into lower cardiovascular risk across the overall study population. He said the study provides critical evidence to advance scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes, which could help guide future strategies for managing cardiovascular risk. He also thanked the more than 8,000 trial participants and investigators.
Full data are to be presented at an upcoming medical congress. Whether any subgroup, such as patients with especially high Lp(a) (搜索), benefited despite the overall result has not been confirmed by Novartis.
Why Lp(a) Was Considered a Clean Test Case
Roughly one in five people carry elevated levels of Lp(a) (搜索). The particle is almost entirely inherited, and diet and exercise barely affect it. It both carries cholesterol into artery walls and makes clotting somewhat more likely once there. Nearly a third of people who develop heart disease young turn out to have high Lp(a). Before pelacarsen, no approved drug was built to target it directly.
That profile made Lp(a) (搜索) an attractive test of a broader assumption: that moving a biomarker in the right direction is equivalent to reducing a patient's actual risk. In this patient population, lowering the number did not lower the outcome.
Implications for CRISPR Therapeutics' Gene-Editing Programs
The readout carries implications for other companies developing Lp(a) (搜索)-lowering treatments. Citi believes the unsuccessful HORIZON outcome increases the likelihood that CRISPR Therapeutics prioritizes CTX321 (搜索), its next-generation Lp(a) program, over its earlier candidate CTX320. CRISPR has described CTX321 as using an updated guide RNA that demonstrated approximately twice the potency of CTX320 in preclinical testing. It uses the same lipid-nanoparticle delivery system and is undergoing studies needed to support regulatory applications for clinical testing. CRISPR expects to provide an update on the program in 2026.
CTX320 has generated Lp(a) (搜索) reductions of as much as 73% during dose escalation, according to CRISPR. The pelacarsen outcome underscores why the ability to lower a biomarker may not be sufficient. Advancing the more potent candidate could give CRISPR a better opportunity to demonstrate a clinically meaningful effect, although that remains unproven. CTX321 (搜索)'s greater preclinical potency does not establish that it will prevent heart attacks or other cardiovascular events in humans, and the candidate remains earlier in development, leaving substantial clinical, regulatory and execution risk. CRISPR has not formally announced that it will abandon CTX320 or make CTX321 its sole priority.
Ionis and the Antisense Platform
Pelacarsen was discovered by Ionis Pharmaceuticals and licensed to Novartis in 2019 for worldwide development and commercialization. The disappointing outcome removes momentum from an important partnered program and weakens a potential validation of Ionis' antisense technology in Lp(a) (搜索)-driven cardiovascular disease (搜索).
Citi analyst Eric Joseph expects less than 5% of immediate downside from the HORIZON result because expectations for pelacarsen were already modest. Following a check-in with management, the firm said it does not expect the result to affect Ionis' fiscal 2026 guidance.
Open Questions for the Field
The failure raises questions about how much Lp(a) (搜索) must be lowered, how long patients must be treated, and whether different therapeutic approaches can deliver better clinical outcomes. Other drugmakers are still pursuing Lp(a) through different molecular routes. The result may slow expectations for how quickly an approved Lp(a) therapy reaches patients, and it adds to evidence that reversing cardiovascular risk later in life may be harder than preventing it from building up earlier.